Search results
Insider Sell Alert: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of ...
GuruFocus.com via Yahoo Finance· 5 months agoHalozyme Therapeutics Inc (NASDAQ:HALO), a biopharmaceutical company focused on developing and...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 months agoHalozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Call Transcript February 20, 2024...
Halozyme Therapeutics Inc's SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares
GuruFocus.com via Yahoo Finance· 3 months agoMichael Labarre, SVP, Chief Technical Officer of Halozyme Therapeutics Inc (NASDAQ:HALO), has sold...
Halozyme Therapeutics Inc (HALO) Reports 15% YoY Increase in Q3 Royalty Revenue, Raises 2023 ...
GuruFocus.com via Yahoo Finance· 6 months agoHalozyme Therapeutics Inc (NASDAQ:HALO) reports a 15% YoY increase in Q3 royalty revenue to a record...
Halozyme Therapeutics Inc (HALO) Reports Strong Year-Over-Year Growth in Q4 and Full Year 2023 ...
GuruFocus.com via Yahoo Finance· 2 months agoRevenue Growth: Q4 revenue increased by 27% YOY to $230 million; full year 2023 revenue up 26% YOY...
Halozyme's (HALO) Q3 Earnings and Revenues Surpass Estimates
Zacks via Yahoo Finance· 1 year agoHalozyme Therapeutics, Inc. HALO reported third-quarter 2022 adjusted earnings of 74 cents per...
Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag
Zacks via Yahoo Finance· 2 months agoHalozyme Therapeutics, Inc. HALO delivered fourth-quarter 2023 adjusted earnings of 82 cents per...
Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y
Zacks via Yahoo Finance· 12 months agoHalozyme Therapeutics, Inc. HALO reported first-quarter 2023 adjusted earnings of 47 cents per...
Analyst Estimates: Here's What Brokers Think Of Halozyme Therapeutics, Inc. (NASDAQ:HALO) After Its...
Simply Wall St. via Yahoo Finance· 2 months agoShareholders of Halozyme Therapeutics, Inc. (NASDAQ:HALO) will be pleased this week, given that the...
Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 63% Above Its Share Price
Simply Wall St. via Yahoo Finance· 12 months agoKey Insights Halozyme Therapeutics' estimated fair value is US$55.16 based on 2 Stage Free Cash Flow...